Toy Manufacturing Startup Bidso Raises ₹63 Cr in Series A Led by Blume Ventures

Bengaluru-based toy manufacturing startup Bidso has secured ₹63 crore in its Series A funding round. This funding was led by Blume Ventures, signaling strong investor confidence in India’s growing manufacturing ecosystem.

The round comprises ₹51 crore in equity and ₹12 crore in venture debt, with participation from existing investors such as Peer Capital and Sadev Capital. The debt component was backed by Alteria Capital.

Strengthening India’s Manufacturing Backbone

Founded as a contract manufacturing platform, Bidso enables brands to streamline the entire production process—from design and engineering to manufacturing and delivery. The startup primarily focuses on categories such as toys and general merchandise, serving businesses seeking efficient, scalable manufacturing solutions.

With this fresh capital, Bidso is expected to expand its manufacturing capabilities, strengthen supply chain infrastructure, and accelerate growth across product categories.

Rising Investor Interest in Manufacturing Startups

The funding comes at a time when investors are increasingly backing India’s manufacturing and supply chain startups, driven by the government’s push to position the country as a global manufacturing hub.

Bidso’s latest round highlights the growing opportunity in contract manufacturing platforms, which help brands reduce operational complexity and improve speed-to-market.

What’s Next for Bidso

With strong backing from institutional investors, Bidso is now poised to:

• Scale its production network.
• Expand into new product categories.
• Strengthen technology-driven manufacturing processes.

As India continues to emerge as a global manufacturing alternative, startups like Bidso are playing a crucial role in shaping the future of “Make in India” initiatives.

Disclaimer

This article is based on publicly available media reports and company disclosures. Kalpway does not independently verify financial or operational claims mentioned in third-party sources. The information provided is for general informational purposes only and should not be considered medical or financial advice